| Literature DB >> 24725668 |
Shubo Li, Xiang Gao, Nan Xu, Liming Liu1, Jian Chen.
Abstract
BACKGROUND: Acetoin is a promising chemical compound that can potentially serve as a high value-added platform for a broad range of applications. Many industrial biotechnological processes are moving towards the use of yeast as a platform. The multi-auxotrophic yeast, Candida glabrata, can accumulate a large amount of pyruvate, but produces only trace amounts of acetoin. Here, we attempted to engineer C. glabrata to redirect the carbon flux of pyruvate to increase acetoin production.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24725668 PMCID: PMC4021295 DOI: 10.1186/1475-2859-13-55
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Figure 1Metabolic pathways of acetoin in : the original and heterologous metabolic pathways. The enzymes that catalyze the pathways were: acetolactate synthase (ILV2 + ILV6, ALS), acetolactate decarboxylase (ALDC), pyruvate decarboxylase (PDC); butanediol dehydrogenase (BDH), acetohydroxy acid isomeroreductase (ILV5). The abbreviations are: BCAAs, branched chain amino acids; 3-PG, 3-phosphate-glyceraldehyde; NOD, non-enzymatic oxidative decarboxylation.
Figure 2Calculation of the heterologous pathway for acetoin production by simulation. The production of acetoin was simulated based on 10 mmol/gDCW/h of glucose uptake from two angles: setting cell growth as the objective function or maximizing acetoin production under 90% of the maximum μ.
Effects of gene over-expression on the enzymes and metabolites
| MuA0 | nt | nt | 0.15 ± 0.01 | 0.11 ± 0.01 | 0.02 ± 0.00 | ND | 0.041 ± 0.002 |
| MuA1 | 0.75 ± 0.05 | 0.58 ± 0.02 | 0.37 ± 0.02 | ND | 0.054 ± 0.003 | ||
| MuA2 | 0.60 ± 0.05 | 0.47 ± 0.03 | 0.33 ± 0.03 | ND | 0.053 ± 0.001 | ||
| MuA3 | 0.81 ± 0.05 | 0.70 ± 0.05 | 0.45 ± 0.02 | ND | 0.077 ± 0.004 | ||
| MuA4 | 0.77 ± 0.1 | 0.62 ± 0.04 | 0.42 ± 0.04 | ND | 0.065 ± 0.002 | ||
| MuA5 | 0.15 ± 0.01 | 0.11 ± 0.01 | ND | 1.85 ± 0.05 | 0.14 ± 0.04 | ||
| MuA6 | 0.14 ± 0.012 | 0.11 ± 0.01 | ND | 1.66 ± 0.05 | 0.12 ± 0.03 | ||
| MuA7 | 0.15 ± 0.02 | 0.12 ± 0.02 | ND | 1.71 ± 0.05 | 0.13 ± 0.06 | ||
| MuA8 | 0.13 ± 0.01 | 0.10 ± 0.02 | ND | 1.57 ± 0.1 | 0.12 ± 0.02 |
aThe engineered strains were grown in fermentation medium, and the production of metabolites in the culture supernatant was determined by HPLC at 64 h during batch flask culture. Results are the average of three replicates with error bars indicating standard error from the mean. ND, Not detected; nt, Not.
The comparison of fermentation characteristics of the engineered strains MuA0 and MuA9
| DCW (g/L) | 10.84 ± 0.6 | 10.34 ± 0.5 | -0.05 |
| Pyruvate (g/L) | 30.7 ± 1.2 | 24.4 ± 0.8 | -0.20 |
| Specific activity of ALS (U/mg protein) | 0.16 ± 0.01 | 0.83 ± 0.04 | 4.19 |
| Specific activity of ALDC (U/mg protein) | ND | 1.86 ± 0.03 | -- |
| Acetolactate (g/L) | 0.12 ± 0.01 | 0.74 ± 0.01 | 5 |
| Acetoin (g/L) | 0.042 ± 0.008 | 1.14 ± 0.05 | 26 |
| Acetoin yield (g/g DCW) | 0.003 | 0.11 | 35 |
| 2,3-Butanediol (g/L) | 0.035 ± 0.004 | 0.88 ± 0.04 | 24 |
| Diacetyl (g/L) | 0.01 ± 0.00 | ND | -- |
| Ethanol (g/L) | 0.87 ± 0.02 | 2.15 ± 0.2 | 1.47 |
| Glycerol (g/L) | 0.66 ± 0.04 | 1.15 ± 0.1 | 0.74 |
aResults are the average of three replicates with error bars indicating standard error from the mean. ND, Not detected.
Figure 3Improvements in the production of acetoin, 2,3-butanediol and ethanol by using different promoters. Results are the average of three replicates with error bars indicating standard error from the mean (MuA9 (PTPI+TPI), MuA10 (PGPD+GPD), MuA11 (PTEF+TEF), MuA12 (PGPD+TEF), MuA13 (PTEF+GPD)).
Effects of different genetic modifications on acetoin fermentation
| DCW (g/L) | 10.27 ± 0.5 | 9.96 ± 0.4 | 10.13 ± 0.5 |
| Pyruvate (g/L) | 18.4 ± 0.7 | 16.8 ± 0.8 | 16.3 ± 1.1 |
| 0.72 ± 0.02 | 0.81 ± 0.01 | 0.74 ± 0.02 | |
| Specific activity of ALS (U/mg protein) | 1.05 ± 0.03 | 1.07 ± 0.05 | 1.04 ± 0.04 |
| Specific activity of ALDC (U/mg protein) | 2.06 ± 0.06 | 2.03 ± 0.05 | 2.10 ± 0.1 |
| Acetoin (g/L) | 1.96 ± 0.3 | 2.13 ± 0.3 | 2.08 ± 0.2 |
| Acetoin yield (g/g DCW) | 0.19 | 0.21 | 0.21 |
| 2,3-Butanediol (g/L) | 1.36 ± 0.03 | 1.45 ± 0.07 | 2.03 ± 0.03 |
| Acetoin/2,3-Butanediol | 1.44 | 1.47 | 1.02 |
| Ethanol (g/L) | 3.67 ± 0.11 | 2.96 ± 0.13 | 2.72 ± 0.2 |
| Acetate (g/L) | 0.64 ± 0.05 | 0.51 ± 0.05 | 0.83 ± 0.1 |
| Glycerol (g/L) | 1.01 ± 0.1 | 1.07 ± 0.12 | 1.12 ± 0.12 |
| Intracellular NAD+ (mg/g DCW) | 16.1 ± 1.2 | 14.6 ± 1.7 | 15.8 ± 2.1 |
| Intracellular NADH/NAD+ ratio | 0.62 | 0.61 | 0.64 |
*The production of metabolites in the culture supernatant was determined by HPLC at 64 h during flask culture. Results were the average of three replicates with error indicating standard error from the mean.
Figure 4Fermentation profiles for the control without the addition of NA (■) and with the addition of NA (▲) in a 5-L fermenter with MuA15. The concentrations of glucose (A), DCW (B), acetoin (C), 2,3-butanediol (D), and ethanol (E), and the intracellular NADH/NAD+ ratio (F) were measured and shown. The values were the mean derived from three independent biological experiments, and error bars indicated the standard deviations.
Strains and plasmids used
| | | |
| pY26 | 2 μm, AmpR, | Lab. collection |
| pYX212 | 2 μm, AmpR, | Lab. collection |
| pY36 | 2 μm, AmpR, | This study |
| pY16 | 2 μm, AmpR, | This study |
| pY46 | 2 μm, AmpR, | This study |
| pYX212- | Codon-optimized | This study |
| pYX212- | Codon-optimized | This study |
| pYX212- | Codon-optimized | This study |
| pYX212- | Codon-optimized | This study |
| pYX212- | Codon-optimized | This study |
| pYX212- | Codon-optimized | This study |
| pYX212- | Codon-optimized | This study |
| pYX212- | Codon-optimized | This study |
| pY16-TPI- | Codon-optimized | This study |
| pY26-TEF- | Codon-optimized | This study |
| pY26-GPD- | Codon-optimized | This study |
| pY36-TEF- | Codon-optimized | This study |
| pY46-GPD- | Codon-optimized | This study |
| | | |
| Multivitamin (thiamine, biotin, nicotinic acid and pyridoxine) auxotroph | [ | |
| The mutant derived from | [ | |
| MuA0 | This study | |
| MuA1 | This study | |
| MuA2 | This study | |
| MuA3 | This study | |
| MuA4 | This study | |
| MuA5 | This study | |
| MuA6 | This study | |
| MuA7 | This study | |
| MuA8 | This study | |
| MuA9 | This study | |
| MuA10 | This study | |
| MuA11 | This study | |
| MuA12 | This study | |
| MuA13 | This study | |
| MuA14 | This study | |
| MuA15 | This study |